The reported incidence of haemorrhagic complications in patients treated with anticoagulated drugs ranges from 12 to 40%. 1-4The first year of anticoagulation carries the highest risk of bleeding. A recent meta-analysis concluded that during this period 5% of bleeding episodes will be life threatening and 1% of patients will die from uncontrolled haemorrhage.5 Subsequently the annual bleeding rate is reduced by about 50°/. The commonest site of significant bleeding is the gastrointestinal tract and this leading article considers the problems of acute, life threatening gastrointestinal bleeding in patients taking oral anticoagulant drugs.
Several reviews have identified factors that influence the source and severity of gastrointestinal bleeding in patients taking anticoagulants. The risk is greatest in those with the most prolonged prothrombin time610; it is increased by concomitant aspirin consumption.11 12 Increasing age, previous gastrointestinal bleeding, atrial fibrillation, and serious coexisting conditions such as renal insufficiency and anaemia are other adverse prognostic factors,3 5 9 10 while the nature of the bleeding site is an obvious important factor. When to reverse anticoagulation? Patients are usually treated with anticoagulants for good reason and the clinician faced with the patient bleeding from the gastrointestinal tract is confronted with the difficult decision of reversing anticoagulation and risking thromboembolic consequences or continuing warfarin and risking exsanguination. Some indications for anticoagulation are more critical than others. Hence the hazards of reversing anticoagulation in a patient receiving anticoagulants for lone atrial fibrillation, transient ischaemic episodes or dilated cardiomyopathy in which the therapeutic INR is 2-3 are less than those for patients treated for prosthetic metal heart valves or frequent pulmonary emboli in whom an INR of 3-4-5 is recommended. For the patient who presents with life threatening bleeding the risks of thrombosis have to be accepted and anticoagulation reversed, not because of the potential hazards of endoscopy (which are probably only slightly increased in patients receiving anticoagulants) but because of the probability that bleeding will continue unless this is done. Furthermore, endoscopic treatment is probably safest done after reversal of anticoagulation and it therefore seems wise to recommend this before endoscopy.
Ideally, controlled reversal of anticoagulation is achieved using prothrombin complex concentration.'8 This is not freely used for gastrointestinal haemorrhage but perhaps should be considered in the most critical patients who are bleeding briskly. In practice fresh frozen plasma is used to replace deficient clotting factors but this may not be as effective. Vitamin KI given by itself is not suitable for active bleeding because it acts slowly. The British National Formulary recommends that vitamin Kl (5 mg) is infused with fresh frozen plasma to correct clotting in patients receiving anticoagulants who are bleeding. Whether this is always correct is a matter of debate; vitamin Kl infusion makes subsequent re-anticoagulation difficult. The extent to which anticoagulation is reversed is not clear; the INR that the clinician aims to achieve after fresh frozen plasma is a compromise between the (unknown) risks of further bleeding and the (unknown) risks of thrombosis in that patient.
Treatment options
For the patient not receiving anticoagulant treatment, endoscopic investigation has become the treatment of choice for a range of bleeding lesions throughout the gastrointestinal tract and surgery is now reserved for the failures of therapeutic endoscopy.19 Until recently the safety and efficacy of these techniques has not been assessed in patients taking anticoagulants but our own experience suggests that, at least for the patient presenting with peptic ulcer haemorrhage, the same is true for patients receiving anticoagulants, as for those not receiving warfarin. 17 We reviewed the clinical course of 23 patients who presented with major peptic ulcer haemorrhage while taking warfarin and compared their outcome with that of a closely matched group of patients who presented with ulcer bleeding in the absence of anticoagulant treatment. The groups were well matched in respect of age, admission haemoglobin concentration, the presence of shock, and endoscopic findings. The INR of the warfarin group was partially corrected using fresh frozen plasma to 1-5-2.5 and endoscopic treatment (injection or the heater probe) was attempted by an experienced endoscopist in all patients. The incidence of uncontrolled bleeding (17 and 18%), need for emergency surgery (9 and 8%) were similar in both groups; the study was too small to make sensible comments about mortality. No significant complications developed in any patient and it seems reasonable, albeit on the basis of this small study, to suggest that patients receiving anticoagulants should be treated endoscopically for bleeding ulcer disease.
The efficacy of endoscopic treatment in patients taking anticoagulants bleeding from the colon has not been criti Longterm outcome The chances of rebleeding after successful haemostatic treatment depend on the underlying cause of bleeding. Our experience suggests that anticoagulation can be safely restarted a few days after haemostasis of bleeding ulcers has been achieved; no further episodes of haemorrhage occurred in our own group of patients receiving anticoagulants over a median follow up period of eight months. Lifelong ulcer healing treatment seems a sensible option in this group.
The outcome for other patients is unclear. A life threatening bleed from vascular malformations is probably a contraindication to re-anticoagulation although decisions have to be based upon relative risks in any single patient. The group of patients who undergo extensive negative investigations for serious haemorrhage are a particularly difficult group. The presumption is often that bleeding has occurred from vascular malformations somewhere in the gut. Again decisions are based upon the severity of bleeding balanced against the indication for anticoagulation. Our own experience suggests that these patients can usually safely be given anticoagulants again with low risk of further major haemorrhage.
Conclusions
All patients who are treated with anticoagulants and present with major gastrointestinal haemorrhage merit endoscopic diagnosis and treatment. Anticoagulation should be reversed in a controlled manner using clotting factors and trying to give some protection against thrombosis while not making subsequent reanticoagulation difficult. Careful consideration is necessary before anticoagulation is restarted after bleeding has been controlled and a less intense anticoagulant regimen considered to balance the risks of rebleeding against those of thromboembolism.
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